Eli Lilly and Company (LLY) 71.58 $LLY FDA clears new

Eli Lilly and Company (LLY) 71.58 $LLY

FDA clears new indication for Lilly's Cyramza
Seeking Alpha - at Seeking Alpha - Fri Apr 24, 4:10PM CDT

LLY: 71.58 (-0.82)

Lilly's CYRAMZA® (ramucirumab) Receives Fourth FDA Approval
PR Newswire - Fri Apr 24, 3:27PM CDT
Eli Lilly and Company (NYSE: LLY) has received its fourth U.S. Food and Drug Administration (FDA) approval for CYRAMZA® (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
LLY: 71.58 (-0.82)

'Non-Cyclical Consumer Healthcare': How This Sector Will Create Long-Term Wealth
Peter Mantas - Seeking Alpha - Fri Apr 24, 1:39PM CDT
Allow me to provide you with a hypothetical portfolio containing only 5 stocks. This portfolio is somewhat diversified in that each company operates in different markets with different threats, competitors and opportunities, but all 5 companies have...
MCK: 229.20 (+0.09), AKRX: 55.24 (-0.68), PFE: 35.27 (-0.09), EW: 138.33 (-3.59), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), MOH: 63.85 (-0.13), ORCL: 43.08 (-0.31), CNC: 73.67 (+1.13), JNJ: 101.08 (+0.62), ANTM: 154.28 (+0.08), VRSK: 72.68 (+0.20), GILD: 103.69 (-1.52), RMD: 65.70 (-7.68), MRK: 57.60 (+0.09), AZN: 71.79 (-1.34), FICO: 93.85 (+0.55), WCN: 46.52 (+0.32), SRCL: 136.94 (-3.56), SNY: 51.75 (-0.01), ACN: 93.40 (-0.44), NVS: 104.28 (-1.22)

Novartis (NVS) Beats on Earnings in Q1, View Reiterated - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 24, 9:00AM CDT
Novartis' core earnings earnings per share came in at $1.33, down from $1.35 in the year-ago period but above the Zacks Consensus Estimate of $1.09.
SHPG: 255.11 (-0.26), LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)

Lilly (Eli( (LLY) Earnings Report: Q1 2015 Conference Call Transcript
at The Street - Fri Apr 24, 3:41AM CDT
The following Lilly (Eli( (LLY) conference call took place on April 23, 2015, 09:00 AM ET. This is a transcript of that earnings call:
LLY: 71.58 (-0.82)

Novartis EPS beats the Street
at Investor's Business Daily - Thu Apr 23, 5:33PM CDT
The drugmaking giant earned $1.29 a share in Q1, up 0.8% from a year earlier, beating views by 19 cents. Novartis' (NVS) net profit quadrupled to $13 bil due to gains on sales of units to Eli Lilly (LLY) and GlaxoSmithKline (GSK). Revenue fell 15% to...
LLY: 71.58 (-0.82), GSK: 46.59 (+0.28), NVS: 104.28 (-1.22)

Eli Lilly
at Investor's Business Daily - Thu Apr 23, 5:31PM CDT
Eli Lilly (LLY) reported Q1 EPS up 24% to 87 cents, topping. Sales fell 1% to $4.644 bil, roughly in line, with higher prices, gains in newer drugs and stronger-than-expected sales in a diabetes drug helping to counter adverse forex and expired...
LLY: 71.58 (-0.82)

Eli Lilly (LLY) Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Apr 23, 4:56PM CDT

LLY: 71.58 (-0.82)

Eli Lilly (LLY) Stock Rises Today Following Earnings Beat
at The Street - Thu Apr 23, 12:45PM CDT
Eli Lilly (LLY) shares are climbing after the company beat analysts first quarter earnings and revenue expectations.
LLY: 71.58 (-0.82)

Eli Lilly (LLY) Crosses Pivot Point Resistance at $72.55
Comtex SmarTrend(R) - Thu Apr 23, 11:49AM CDT
Shares of Eli Lilly (NYSE:LLY) have bullishly opened above the pivot of $72.22 today and have reached the first resistance level of $72.55. Should the shares continue to rise, the resistance pivots of $72.81 and $73.40 will be of interest.
LLY: 71.58 (-0.82)

Eli Lilly Beats on 1Q Earnings by Wide Margin, Affirms View - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Apr 23, 9:50AM CDT
Eli Lilly's (LLY) first quarter earnings were better than expected despite the presence of generics and unfavorable currency movement.
AGEN: 7.12 (+0.75), BIIB: 401.71 (-28.57), AVEO: 1.92 (-0.08), LLY: 71.58 (-0.82)

Eli Lilly And (LLY): Stock With Unusual Social Activity
at The Street - Thu Apr 23, 8:48AM CDT
Trade-Ideas LLC identified Eli Lilly and (LLY) as an unusual social activity candidate
LLY: 71.58 (-0.82)

IBC Advanced Alloys CEO Anthony Dutton a Speaker at Smart Manufacturing Summit 2015
Marketwired - Thu Apr 23, 8:03AM CDT
IBC Advanced Alloys Corp. (TSX VENTURE: IB)(OTCQX: IAALF) ("IBC" or the "Company", a leading advanced alloys and precision castings company, announces that Anthony Dutton, President and CEO of IBC Advanced Alloys Corp. will be a featured speaker at the 3rd annual Smart Manufacturing Summit being held April 28 - 30, 2015 in Indianapolis, Indiana and hosted by Chief Executive Magazine.
SWK: 99.79 (+0.02), IB.VN: 0.130 (-0.005), LLY: 71.58 (-0.82), CSCO: 28.82 (+0.15)

Eli Lilly and (LLY) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Apr 23, 7:55AM CDT

LLY: 71.58 (-0.82)

Eli Lilly (LLY) Beats on 1Q Earnings & Revenues - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 23, 6:56AM CDT
Eli Lilly (LLY) Beats on 1Q Earnings & Revenues
LLY: 71.58 (-0.82)

Eli Lilly Q1 sales flat; net income down 27%; EPS guidance lowered
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 6:56AM CDT

LLY: 71.58 (-0.82)

Lilly tops Street 1Q forecasts
AP - Thu Apr 23, 5:46AM CDT
INDIANAPOLIS (AP) — Eli Lilly and Co. (LLY) on Thursday reported first-quarter net income of $529.5 million.
LLY: 71.58 (-0.82)

Eli Lilly beats by $0.10, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Apr 23, 5:29AM CDT

LLY: 71.58 (-0.82)

Lilly Reports First-Quarter 2015 Results
PR Newswire - Thu Apr 23, 5:25AM CDT
-- Revenue declined 1 percent due to the unfavorable impact of foreign exchange rates and the continuing impact of Cymbalta and Evista patent expirations, largely offset by the inclusion of revenue from Novartis Animal Health, higher U.S. prices, and increased volume for several products.
LLY: 71.58 (-0.82), NVS: 104.28 (-1.22)